Cargando…

Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“

The key priority in patients with chronic lung diseases is currently immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); all vaccines approved for this showed high effectiveness against severe infections. For patients with chronic pulmonary diseases the recommendations...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodt, Carolin, Pletz, Mathias W., Kolditz, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
CME
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274260/
https://www.ncbi.nlm.nih.gov/pubmed/34276271
http://dx.doi.org/10.1007/s10405-021-00402-4
_version_ 1783721526707617792
author Dodt, Carolin
Pletz, Mathias W.
Kolditz, Martin
author_facet Dodt, Carolin
Pletz, Mathias W.
Kolditz, Martin
author_sort Dodt, Carolin
collection PubMed
description The key priority in patients with chronic lung diseases is currently immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); all vaccines approved for this showed high effectiveness against severe infections. For patients with chronic pulmonary diseases the recommendations by the Standing Committee on Vaccination include not only the standard vaccinations in adulthood but also the so-called indication vaccinations. These include vaccinations against pneumococci and influenza. Advances include the recent development of new pneumococcal conjugate vaccines containing additional serotypes and the recommendation of a more effective high-dose vaccine against influenza for persons over 60 years old. With the next scheduled booster vaccination against tetanus and diphtheria a combination vaccine with pertussis antigen should be used. For patients with chronic lung disease the herpes zoster vaccine is recommended over the age of 50 years.
format Online
Article
Text
id pubmed-8274260
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-82742602021-07-12 Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“ Dodt, Carolin Pletz, Mathias W. Kolditz, Martin Pneumologe (Berl) CME The key priority in patients with chronic lung diseases is currently immunization against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); all vaccines approved for this showed high effectiveness against severe infections. For patients with chronic pulmonary diseases the recommendations by the Standing Committee on Vaccination include not only the standard vaccinations in adulthood but also the so-called indication vaccinations. These include vaccinations against pneumococci and influenza. Advances include the recent development of new pneumococcal conjugate vaccines containing additional serotypes and the recommendation of a more effective high-dose vaccine against influenza for persons over 60 years old. With the next scheduled booster vaccination against tetanus and diphtheria a combination vaccine with pertussis antigen should be used. For patients with chronic lung disease the herpes zoster vaccine is recommended over the age of 50 years. Springer Medizin 2021-07-12 2021 /pmc/articles/PMC8274260/ /pubmed/34276271 http://dx.doi.org/10.1007/s10405-021-00402-4 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle CME
Dodt, Carolin
Pletz, Mathias W.
Kolditz, Martin
Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“
title Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“
title_full Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“
title_fullStr Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“
title_full_unstemmed Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“
title_short Prävention durch Impfung pneumologisch vorerkrankter Erwachsener: Pneumokokkenpneumonie, Influenza, Pertussis, Herpes Zoster und „coronavirus disease 2019“
title_sort prävention durch impfung pneumologisch vorerkrankter erwachsener: pneumokokkenpneumonie, influenza, pertussis, herpes zoster und „coronavirus disease 2019“
topic CME
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274260/
https://www.ncbi.nlm.nih.gov/pubmed/34276271
http://dx.doi.org/10.1007/s10405-021-00402-4
work_keys_str_mv AT dodtcarolin praventiondurchimpfungpneumologischvorerkranktererwachsenerpneumokokkenpneumonieinfluenzapertussisherpeszosterundcoronavirusdisease2019
AT pletzmathiasw praventiondurchimpfungpneumologischvorerkranktererwachsenerpneumokokkenpneumonieinfluenzapertussisherpeszosterundcoronavirusdisease2019
AT kolditzmartin praventiondurchimpfungpneumologischvorerkranktererwachsenerpneumokokkenpneumonieinfluenzapertussisherpeszosterundcoronavirusdisease2019